Effect of teriparatide on early bone loss after kidney transplantation

American Journal of Transplantation

Volumn 8, Issue 9, 2008, Pages 1864-1870

  Cejka, D ^a   Benesch, T ^a   Krestan, C ^a   Roschger, P ^b   Klaushofer, K ^b   Pietschmann, P ^a   Haas, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Kidney transplantation; Recombinant PTH; Renal osteodystrophy

Indexed keywords

PARATHYROID HORMONE[1-34]; PLACEBO;

ADULT; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MINERALIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMUR NECK; FRACTURE; HUMAN; INJECTION SITE ERYTHEMA; KIDNEY TRANSPLANTATION; LUMBAR SPINE; MORPHOMETRICS; OSTEOLYSIS; PRIORITY JOURNAL; RADIUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BIOPSY; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CALCIFEDIOL; CALCITRIOL; CREATININE; DOUBLE-BLIND METHOD; FEMALE; FEMUR NECK; HUMANS; KIDNEY TRANSPLANTATION; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOCALCIN; PARATHYROID HORMONE; RADIUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; TERIPARATIDE; TIME FACTORS;

EID: 49649090635     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02327.x     Document Type: Article

References (32)

1. Kodras K, Haas M. Effect of kidney transplantation on bone. Eur J Clin Invest 2006 36 (Suppl 2 63 75.
2. Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation 1994 58 : 912 915.
3. Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999 33 : 829 839.
4. Cohen A, Sambrook P, Shane E. Management of bone loss after organ transplantation. J Bone Miner Res 2004 19 : 1919 1932
5. Palmer S, McGregor DO, Strippoli G. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev 2007 18 : CD005015.
6. National Kidney Foundation : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 42 (4 Suppl 3 S1 S201.
7. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.8. Bone disease. Nephrol Dial Transplant 2002 17 (Suppl 4 43 48
8. Julian BA, Laskow DA, Dubovsky J, Dubovsky, EV, Curtis JJ, Quarles LD. Rapid bone loss of vertebral mineral density after renal transplantation. N Engl J Med 1991 325 : 544 550.
9. Haas M, Leko-Mohr Z, Roschger P et al. Zoledronic acid to prevent bone loss in the first six months after renal transplantation. Kidney Int 2003 63 : 1130 1136.
10. Coco M, Glicklich D, Faugere MC et al. Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003 14 : 2669 2676.
11. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001 344 : 1434 1441.
12. Black DM, Greenspan SL, Ensrud KE et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003 349 : 1207 1215.
13. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003 349 : 1216 1226.
14. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomised controlled trial. J Clin Invest 1998 102 : 1627 1633.
15. Saag KE, Shane E, Boonen S et al. Teriparatide or alendronate in glucocorticoid induced osteoporosis. N Engl J Med 2007 15 : 2028 2039.
16. Parfitt AM, Drezner MK, Glorieux FH et al. Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987 2 : 595 610.
17. Roschger P, Fratzl P, Eschberger J, Klaushofer K. Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies. Bone 1998 23 : 319 326.
18. Roschger P, Gupta HS, Berzlanovich A et al. Constant mineralization density distribution in cancellous human bone. Bone 2003 32 : 316 323.
19. Roschger P, Paschalis EP, Fratzl P, Klaushofer K. Bone mineralization density distribution in health and disease. Bone 2007 42 : 456 466.
20. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000 85 : 3069 3076.
21. Lindsay R, Nieves J, Formica C et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997 350 : 550 555.
22. Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP, Phipps R, Klaushofer K. Evidence that treatment with Risedronate in women with postmenopausal osteoporosis effects bone mineralization and bone volume. Calcif Tissue Int 2007 81 : 73 80.
23. Misof BM, Roschger P, Cosman F et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 2003 88 : 1150 1156.
24. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006 21 : 1785 1790.
25. Lippuner K, Casez JP, Horber FF, Jaeger P. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: A randomized, double blind study in kidney transplant patients. J Clin Endocrinol Metabol 1998 83 : 3795 3802.
26. Iwasaki Y, Yamato H, Nii-Kono T et al. Insufficiency of PTH action on bone in uremia. Kidney Int Suppl 2006 102 : S34 S36.
27. Malluche HH, Koszewski N, Monier-Faugere MC, Williams JP, Mawad H. Influence of the parathyroid glands on bone metabolism. Eur J Clin Invest 2006 36 : 23 33.
28. Mathew S, Davies M, Lund R, Saab G, Hruska KA. Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease. Eur J Clin Invest 2006 36 : 43 50.
29. Borchhardt K, Sulzbacher I, Benesch T, Födinger M, Sunder-Plassmann G, Haas M. Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Transplant 2007 7 : 2515 2521.
30. Rojas E, Carlini RG, Clesca P et al. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int 2003 6 : 1915 1923.
31. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999 104 : 371 373.
32. Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 2000 11 : 1093 1099.